PT  - JOURNAL ARTICLE
AU  - Washington, Nicole L.
AU  - Gangavarapu, Karthik
AU  - Zeller, Mark
AU  - Bolze, Alexandre
AU  - Cirulli, Elizabeth T.
AU  - Barrett, Kelly M. Schiabor
AU  - Larsen, Brendan B.
AU  - Anderson, Catelyn
AU  - White, Simon
AU  - Cassens, Tyler
AU  - Jacobs, Sharoni
AU  - Levan, Geraint
AU  - Nguyen, Jason
AU  - Ramirez, Jimmy M.
AU  - Rivera-Garcia, Charlotte
AU  - Sandoval, Efren
AU  - Wang, Xueqing
AU  - Wong, David
AU  - Spencer, Emily
AU  - Robles-Sikisaka, Refugio
AU  - Kurzban, Ezra
AU  - Hughes, Laura D.
AU  - Deng, Xianding
AU  - Wang, Candace
AU  - Servellita, Venice
AU  - Valentine, Holly
AU  - De Hoff, Peter
AU  - Seaver, Phoebe
AU  - Sathe, Shashank
AU  - Gietzen, Kimberly
AU  - Sickler, Brad
AU  - Antico, Jay
AU  - Hoon, Kelly
AU  - Liu, Jingtao
AU  - Harding, Aaron
AU  - Bakhtar, Omid
AU  - Basler, Tracy
AU  - Austin, Brett
AU  - Isaksson, Magnus
AU  - Febbo, Phillip G.
AU  - Becker, David
AU  - Laurent, Marc
AU  - McDonald, Eric
AU  - Yeo, Gene W.
AU  - Knight, Rob
AU  - Laurent, Louise C.
AU  - de Feo, Eileen
AU  - Worobey, Michael
AU  - Chiu, Charles
AU  - Suchard, Marc A.
AU  - Lu, James T.
AU  - Lee, William
AU  - Andersen, Kristian G.
TI  - Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
AID  - 10.1101/2021.02.06.21251159
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.06.21251159
4099  - http://medrxiv.org/content/early/2021/02/07/2021.02.06.21251159.short
4100  - http://medrxiv.org/content/early/2021/02/07/2021.02.06.21251159.full
AB  - As of January of 2021, the highly transmissible B.1.1.7 variant of SARS-CoV-2, which was first identified in the United Kingdom (U.K.), has gained a strong foothold across the world. Because of the sudden and rapid rise of B.1.1.7, we investigated the prevalence and growth dynamics of this variant in the United States (U.S.), tracking it back to its early emergence and onward local transmission. We found that the RT-qPCR testing anomaly of S gene target failure (SGTF), first observed in the U.K., was a reliable proxy for B.1.1.7 detection. We sequenced 212 B.1.1.7 SARS-CoV-2 genomes collected from testing facilities in the U.S. from December 2020 to January 2021. We found that while the fraction of B.1.1.7 among SGTF samples varied by state, detection of the variant increased at a logistic rate similar to those observed elsewhere, with a doubling rate of a little over a week and an increased transmission rate of 35-45%. By performing time-aware Bayesian phylodynamic analyses, we revealed several independent introductions of B.1.1.7 into the U.S. as early as late November 2020, with onward community transmission enabling the variant to spread to at least 30 states as of January 2021. Our study shows that the U.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.Competing Interest StatementNLW, AB, ETC, KMSB, SW, CRG, ES, TC, XW, JN, JMR, GL, DW, DB, ML, MI, SJ, JTL, and WL are employees of Helix. KG, BS, JA, KH, JL, EdF, and PGF are employees of Illumina. JN, CRG, ML own stock in ILMN.Funding StatementThis work has been funded by CDC BAA contracts 75D30121P10258 (Illumina, Helix) and 75D30120C09795 (GWY, RK, LCL, KGA), NIH NIAID 3U19AI135995-03S2 (MAS, KGA), U19AI135995 (MAS, KGA), U01AI151812 (KGA), NIH NCATS UL1TR002550 (KGA), the Innovative Genomics Institute (CYC), and the New Frontiers in Research Fund provided by the Canadian Institutes of Health Research (CYC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)). This work was also evaluated and approved by the Institutional Review Board at The Scripps Research Institute under IRB protocol IRB-15-6664. The work was conducted under a waiver of consent and received a non-human subjects research designation (category 4 exemption) because this research was performed with remnant clinical diagnostic specimens. All samples were de-identified before receipt by the study investigators.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data and processing scripts are available at https://github.com/andersen-lab/paper_2021_early-b117-usa; Viral sequences have been deposited at GISAID, with accession numbers as listed in Supplemental Tables.; Additionally, continuing monitoring of the phenomena described in the manuscript can be found at https://www.helix.com/covid19db https://github.com/andersen-lab/paper_2021_early-b117-usa https://www.helix.com/covid19db